Radiopharm Theranostics Limited American Depositary Shares logo

Radiopharm Theranostics Limited American Depositary Shares(RADX)

upturn advisory logo
EXPLORE ADVISORIES AND THEIR HISTORY
QUALITY SIGNAL
1-STAR RATING
PASS
LAST CLOSE
$0.76
11/13/2026
(24-hour delay)

Advisory History & Simulated Performance *

*as per simulation (see disclosures)
  • ALL
  • 1Y
  • 1M
  • 1W
  • BUY Advisory
  • SELL Advisory (Profit)
  • SELL Advisory (Loss)
  • Profit
  • Loss
  • PASS (Skip)
Upturn Stock price based on last close iconStock price based on last close
Simulated performance—not actual client returns. Excludes advisory subscription fees, trading commissions, and taxes, which would reduce returns. Results depend on calculation assumptions and do not guarantee future outcomes. See Disclosures for full methodology, assumptions, and limitations.

Advisory Performance History (Simulated)Advisory Performance History info

Simulated performance—not actual client returns. Excludes advisory subscription fees, trading commissions, and taxes, which would reduce returns. Results depend on calculation assumptions and do not guarantee future outcomes. See Disclosures for full methodology, assumptions, and limitations.

Upturn Advisory & Investor View for RADX

11/13/2026: RADX (1-star) is currently NOT-A-BUY. Pass it for now.

Radiopharm Theranostics is a clinical-stage biotechnology company focused on developing radiopharmaceutical agents for cancer diagnosis and treatment. Its core strength lies in a diverse pipeline of targeted therapies that aim to address significant gaps in oncology care. While the company offers a compelling growth opportunity through its platform-based approach, it faces substantial risks, including a lack of current revenue, clinical trial execution uncertainty, and intense competition from much larger pharmaceutical firms. The stock is best suited for growth-oriented investors who understand the high volatility of early-stage biotech. Investors should closely monitor clinical data releases and potential strategic partnerships for signs of progress.

How to Read the Upturn Advisory

The Upturn Star Rating and the current BUY, SELL, or PASS advisory are generated by Upturn’s AI advisory engine based on proprietary signal analysis, price behavior, advisory history, and historical signal performance.

Company fundamentals, valuation, risks, and news provide supporting context about the business.

Investor Fit

Investor styleFitWhy
Growth investorMixed fitThis is a high-risk, high-reward play suitable only for investors with an appetite for pre-revenue biotech development.
Momentum investorMixed fitThe stock can see speculative spikes on clinical news, making it conditionally interesting during positive trial updates.
Value investorWeak fitTraditional valuation metrics are not applicable to this pre-revenue entity.
Dividend investorWeak fitThe company has no revenue and pays no dividends.
Low-risk investorWeak fitThe high volatility and clinical risk profile are unsuitable for conservative portfolios.

Risk Profile

Risk factorLevelWhy it matters
Price volatilityHighSpeculative biotech stocks often experience extreme price swings based on trial data and capital market sentiment.
Valuation riskHighWithout revenue, it is difficult to determine an intrinsic floor for the stock price.
Competition risk (Major Pharma)Medium / highBetter-capitalized competitors could bring rival therapies to market faster.
Business qualityMediumThe company is in a formative stage with unproven clinical assets.
Dividend incomeLow / noneInvestors should expect zero income from this holding.
Execution riskHighThe company must successfully navigate complex global clinical and regulatory requirements.

Key Highlights

Company Size Small-Cap Stock
Market Capitalization 11.93M USD
Price to earnings Ratio -
1Y Target Price 16.53
Price to earnings Ratio -
1Y Target Price 16.53
Volume (30-day avg) 52.2K shares
Beta 0.87
52 Weeks Range 0.74 - 10.63
Updated Date 11/14/2026
52 Weeks Range 0.74 - 10.63
Updated Date 11/14/2026
Dividends yield (FY) -
Basic EPS (TTM) -3.5

Sector & Industry Intelligence

Sector

Healthcare

Bullish
Sentiment
Strong Bullish
Momentum
Momentum Steady
BUY participation
62.6%
Active BUY / eligible
72 / 115
30-Day BUY Count Change
+35
Market state
Strong Bullish

The number of qualifying BUY stocks has remained relatively stable.

Industry

Biotechnology

BUY participation
45.5%
Active BUY / eligible
20 / 44
30-Day BUY Count Change
+13

Sector signal summarizes BUY breadth conditions for the sector. It does not override this stock’s BUY, SELL, or PASS advisory.

Price Behavior

Steep Decline
PRICE PATH

Steep Decline

The stock price has dropped sharply with strong downward pressure.

Highly Choppy
PRICE STABILITY

Highly Choppy

The stock has experienced frequent, large price swings that make its near-term movement less predictable.

Analysis of Past Performance

Type Stock
Historic Profit -32.12%
Avg. Invested days 30
Today’s Advisory PASS
Upturn Advisory Rating upturn star rating icon
Upturn Advisory Performance Upturn Advisory Performance icon 2.0
Stock Returns Performance Upturn Returns Performance icon 1.0
Upturn Profits based on simulation icon Profits based on simulation
Upturn last close icon Last Close 11/13/2026

Upturn Scorecard

Upturn Star Rating

★★★★★
RADX receives a 2-star rating, supported by solid analyst coverage. The rating is constrained by weak unit economics, soft company fundamentals, and weak price momentum.

Company Fundamentals

★★★★★
RADX has soft overall fundamentals (2 stars), with weak financial health, weak growth momentum, and soft ownership. In FY2026 versus FY2025, growth and ownership metrics are mixed: negative earnings growth (-40.7%), weak cash generation (FCF margin -1949.6%), negative revenue growth (-25.5%).

Financial Health Rating

★★★★★
RADX's financial health is weak, with the relatively strongest area being soft liquidity, including working-capital and asset support (WC/assets 5.0%). Operating efficiency is weak (1 stars), which helps explain the 1-star overall score.

Growth Momentum Score

★★★★★
RADX's growth profile is soft, with the least-weak measure being revenue growth at -25.5% FY2026 versus FY2025. By comparison, while earnings growth (-40.7%, negative) and free-cash-flow growth (-44.0%, negative) hold the profile back, so recent growth is not broad-based across the business.

Ownership

★★★★★
Institutional ownership is 0.8% (soft) and 76.2% of outstanding shares are publicly tradable (solid). Insider ownership is only 0.00%, which materially reduces the ownership score.

Top 5 Institutional Investors

HSBC Holdings PLC 0.53%
VGI Partners Ltd 0.34%
PNC Financial Services Group Inc 0.17%
UBS Group AG 0.01%
Integrated Wealth Concepts LLC 0.01%

Unit Economics (Per $1K Revenue)

★★★★★
RADX generates approximately $-777 of gross profit, $-24,686 of operating income, and $-19,496 of free cash flow for every $1,000 of revenue. Based on FY2026 results. Operating losses and cash burn explain the 1-star rating, with weak cash conversion and weak capital efficiency.

Economic Dimensions

★★★★★
Effective Tax Rate: 0.10%

Quantitative Style Profile

★★★★★
RADX has a liquid profile. Weak momentum is the primary drawback.

Style Classification

Quality Focused

Value-OrientedSmall / Mid Cap RiskHighly Liquid / Institution-Friendly

How Company Makes Money

Business areaWhat it includesRetail investor read
Radiopharmaceutical DevelopmentClinical trial assets RAD 301 and RAD 204.The company currently makes no money; it is burning cash to develop experimental cancer drugs.

Analyzing Revenue: Products, Geography and Growth

Revenue by Geography

Geography revenue - Year on Year

Valuation

Trailing PE -
Forward PE -
Enterprise Value 10.10M
Price to Sales(TTM) 0.93
Enterprise Value 10.10M
Price to Sales(TTM) 0.93
Enterprise Value to Revenue 5.31
Enterprise Value to EBITDA -
Shares Outstanding 15.70M
Shares Floating 11.96M
Shares Outstanding 15.70M
Shares Floating 11.96M
Percent Insiders -
Percent Institutions 0.85

Financial Metrics

🧭 Investment Snapshot

Total Revenue (Scale)

Information icon Total money earned from selling products or services before any costs. It is needed to understand the scale of the business and its ability to generate income.

Net Income (Profit)

Information icon Final profit after all expenses, interest, and taxes are deducted. It is needed to determine the overall profitability available to shareholders.

Free Cash Flow (Cash Strength)

Information icon Cash remaining after operating activities and capital expenditures, showing cash available for growth. It is needed to evaluate the company’s ability to invest, pay dividends, or reduce debt.

📈 Growth & Strength

Operating Income (Core Profit)

Information icon Profit from core operations after deducting all operating expenses. It is needed to measure how efficiently the company runs its primary business activities.

EBITDA (Cash Earnings)

Information icon Earnings before interest, taxes, depreciation, and amortization, indicating operating cash potential. It is needed to compare operating performance across companies without accounting or financing differences.

Gross Profit (Unit Profitability)

Information icon Revenue minus cost of revenue, showing profit after direct production costs. It is needed to evaluate core business profitability before overhead expenses.

🛡️ Financial Safety

Cash (Liquidity Buffer)

Information icon Total cash and cash equivalents on hand. It is needed to evaluate immediate liquidity and financial flexibility.

Total Debt (Leverage Risk)

Information icon Total debt including both short-term and long-term components. It is needed to assess the company’s leverage and financial risk.

Net Working Capital (Short-Term Health)

Information icon Current assets minus current liabilities, indicating short-term liquidity strength. It is needed to assess whether the company can meet its short-term obligations.

🧱 Balance Sheet Strength

Stockholder Equity (Net Worth)

Information icon Total equity value held by shareholders. It is needed to understand the net worth of the company from the owners’ perspective.

Total Assets (Asset Base)

Information icon The full value of everything the company owns, including cash, inventory, equipment, and investments. It is needed to understand the resource base used to generate revenue.

Income Before Tax (Pre-Tax Earnings)

Information icon Income before provision for income taxes. It is needed to analyze profitability independent of tax structures.

⚙️ Cost & Drag Factors

Cost of Revenue (Production Cost)

Information icon Direct costs required to produce and deliver the products or services sold. It is needed to assess efficiency in production and service delivery.

Total Operating Expenses (Operating Cost)

Information icon Indirect costs of running the business such as salaries, marketing, and administration. It is needed to understand how much it costs to sustain ongoing business operations.

Income Tax Expense (Tax Drag)

Information icon Amount of taxes paid or payable to the government. It is needed to evaluate the impact of taxation on overall profitability.

Form CRS provides a relationship summary of our automated advisory services, flat subscription fees, and conflicts of interest. Form ADV Part 2A brochure contains complete details on services, billing, and disclosures. If any summary differs from our current regulatory filings, the filed Form ADV controls.